Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.

Item

http://www.wikidata.org/entity/Q38473460

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Immunogenicity of biologic tre ...... e of concomitant methotrexate.

@en

type

Item

label

Immunogenicity of biologic tre ...... e of concomitant methotrexate.

@en

prefLabel

Immunogenicity of biologic tre ...... e of concomitant methotrexate.

@en

P1476

Immunogenicity of biologic tre ...... e of concomitant methotrexate.

@en

P2093

Michael E Farhangian

http://www.w3.org/2001/XMLSchema#string

Steven R Feldman

http://www.w3.org/2001/XMLSchema#string

P2860

Radioimmunoassay, enzyme and non-enzyme-based immunoassays

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

P2888

s40257-015-0131-y

P304

285-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40257-015-0131-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043295710

http://www.w3.org/2001/XMLSchema#string

P698

25963062

http://www.w3.org/2001/XMLSchema#string